Chronic spontaneous urticaria and chronic inducible urticaria.
Lee R, Bernstein JA.
J Allergy Clin Immunol. 2025 Sep;156(3):546-556. doi: 10.1016/j.jaci.2025.05.019. Epub 2025 May 30.
Chronic inducible urticaria: classification and prominent features of physical and non-physical types.
Pozderac I, Lugović-Mihić L, Artuković M, Stipić-Marković A, Kuna M, Ferček I.
Acta Dermatovenerol Alp Pannonica Adriat. 2020 Sep;29(3):141-148.
Biomarkers of Autoimmune Chronic Spontaneous Urticaria.
Larenas-Linnemann D.
Curr Allergy Asthma Rep. 2023 Dec;23(12):655-664. doi: 10.1007/s11882-023-01117-7. Epub 2023 Dec 8.
Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria.
Terhorst-Molawi D, Hawro T, Grekowitz E, Kiefer L, Merchant K, Alvarado D, Thomas LJ, Hawthorne T, Crowley E, Heath-Chiozzi M, Metz M, Maurer M.
Allergy. 2023 May;78(5):1269-1279. doi: 10.1111/all.15585. Epub 2022 Dec 3.
Neutrophilic urticarial dermatosis: A review.
Gusdorf L, Lipsker D.
Ann Dermatol Venereol. 2018 Dec;145(12):735-740. doi: 10.1016/j.annder.2018.06.010. Epub 2018 Sep 14.
The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease.
Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, D'Agostino D, Planavsky N, Lupfer C, Kanneganti TD, Kang S, Horvath TL, Fahmy TM, Crawford PA, Biragyn A, Alnemri E, Dixit VD.
Nat Med. 2015 Mar;21(3):263-9. doi: 10.1038/nm.3804. Epub 2015 Feb 16.
Chronic urticaria and autoinflammatory syndromes.
Yacoub MR, Ferlito A, Nettis E.
Curr Opin Allergy Clin Immunol. 2025 Oct 1;25(5):411-417. doi: 10.1097/ACI.0000000000001093. Epub 2025 Aug 1.
KCNN4 links PIEZO-dependent mechanotransduction to NLRP3 inflammasome activation.
Ran L, Ye T, Erbs E, Ehl S, Spassky N, Sumara I, Zhang Z, Ricci R.
Sci Immunol. 2023 Dec 22;8(90):eadf4699. doi: 10.1126/sciimmunol.adf4699. Epub 2023 Dec 22.
Water-related dermatoses.
Hamie L, Abou-Rahal J.
Int J Dermatol. 2019 May;58(5):515-529. doi: 10.1111/ijd.14316. Epub 2018 Dec 2.
Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.
Arnold DD, Yalamanoglu A, Boyman O.
Front Immunol. 2022 Jul 6;13:888392. doi: 10.3389/fimmu.2022.888392. eCollection 2022.
